Winning Stock Forecast: Arrowhead Pharmaceuticals (NASDAQ: ARWR) Returns up to 321.18% in 1 Year


Since the beginning of 2018 Arrowhead Pharmaceuticals showed growth catalysts for this year. First, according to the quarterly report for the period ended December 31, 2017, on September 28, 2016 the Company entered into a collaboration agreement with Amgen Inc. The Company received a worldwide license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target, that makes Amgen wholly responsible for clinical development and commercialization of this technology. Moreover, the

Read More

Winning ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc Jumped Up 87.41% In 3 Months After Strong Buy Prediction

“The ARO-AAT Phase 1 study provides the first readout on pharmacologic activity for a therapeutic leveraging our proprietary Targeted RNAi Molecule, or TRiM™, platform. We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated.”

– Chris Anzalone, Ph.D., President and CEO of Arrowhead

(Source: Wikimedia Commons)

For three months since March 28th, 2018, Arrowhead Pharmaceuticals Inc (NYSE: ARWR) has gained 87.41%, becoming one of the most profitable stocks in pharmaceuticals industry. The success

Read More

Quick Win by the Algorithm: Amgen partnership looks to provide significant upside for ARWR in 2018

Stock Prediction Quick Win

Read The Full Forecast